Piper Sandler lowered the firm’s price target on CVS Health (CVS) to $64 from $72 and keeps an Overweight rating on the shares. The firm believes CVS has multiple, viable paths to 100-200 bps of MA margin expansion in 2025. Best-in-class Star ratings lend visibility to 2026 and position the Aetna MA franchise for durable earnings growth through this rate cycle and into the next.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- Trump Weekly: Trump looks to drop EV tax credit, fuel-efficiency requirements
- Trump Trade: Transition team weighing White House crypto role
- CVS (NYSE:CVS), UnitedHealth and Cigna File Suit Against the Federal Trade Commission
- Kennedy Jr. considers upheaval to U.S. Medicare billing system, FT says
- Trump Trade: Apollo CEO to be interviewed for Treasury Secretary role